Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 5, 2026 | $0.36 | +24.1% | $256.15M | +31.7% | $0.05 |
| Q1 FY26ended Mar 31, 2026 | May 6, 2026 | −$0.30 | −276.5% | $164.90M | +4.9% | −$0.17 |
| Q4 FY25ended Dec 31, 2025 | — | $0.20 | −23.1% | $202.13M | +11.1% | — |
| Q3 FY25ended Sep 30, 2025 | — | $0.16 | −61.0% | $207.64M | +13.7% | — |
| Q2 FY25ended Jun 30, 2025 | — | $0.29 | −9.4% | $194.43M | +18.7% | — |
| Q1 FY25ended Mar 31, 2025 | — | $0.17 | −32.0% | $157.21M | +7.1% | — |
| Q4 FY24ended Dec 31, 2024 | — | $0.26 | −7.1% | $181.89M | +34.3% | — |
| Q3 FY24ended Sep 30, 2024 | — | $0.41 | +46.4% | $182.55M |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Corcept Therapeutics shares, not any token. As of Aug 5, 2026, from Massive's standardised financials and the earnings calendar.
| +47.7% |
| — |
| Q2 FY24ended Jun 30, 2024 | — | $0.32 | — | $163.80M | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $0.25 | — | $146.81M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $0.28 | — | $135.41M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $0.28 | — | $123.60M | — | — |